Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 60 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care showed no clear difference in in‐hospital mortality at up to day 150 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care probably leads to higher clinical improvement: participants alive and ready to be discharged… compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care probably leads to lower clinical worsening: time to new need for invasive mechanical… compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
Remdesivir and standard care showed no clear difference in serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
It is very uncertain whether remdesivir and standard care changes clinical improvement: participants with symptom alleviation at up to… compared with standard care (plus/minus placebo) (very low certainty).
The intervention probably leads to lower 28‐day all‐cause mortality (moderate certainty).
The intervention showed no clear difference in thrombotic events up to day 45 (low certainty).
The intervention showed no clear difference in serious adverse events up to day 45 (low certainty).
The intervention showed no clear difference in worsening up to day 28: participants with new need for invasive… (moderate certainty).
The intervention showed no clear difference in improvement up to day 28: participants discharged alive (moderate certainty).
The intervention showed no clear difference in all‐cause mortality at day 45 (low certainty).
It is very uncertain whether the intervention changes admission to hospital or death up to day 45 (very low certainty).
Hyperimmune immunoglobulin from human plasma showed no clear difference in all‐cause mortality at day 28 compared with saline placebo (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in improvement of clinical status (number of participants discharged… compared with saline placebo (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.